Laboratory Corporation of America Plasma Focus

Labcorp has launched its Plasma Focus liquid biopsy test, which analyzes cell-free DNA to enable targeted therapy selection for patients with advanced or metastatic solid tumors. The test in intended for use in patients with non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, and gastric cancers, and melanoma, and is meant as a complement to tissue-based genomic testing, particularly when tissue is not available or accessible. It uses next-generation sequencing for the detection of genomic sequence mutations in 33 clinically actionable or relevant genes, including amplifications in eight genes, translocations associated with five genes, and microsatellite instability.